SNG Insider Trading (Synairgen)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £1,173.69
Insider Selling (Last 12 Months): £377,948.20
Synairgen Share Price & Price History
Current Price: GBX 29.67
Price Change: ▲ Price Increase of +1.069 (3.74%)
As of 05/20/2022 03:20 PM ET
This is the golden age of investing in artificial intelligence!
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive.
Invest in this red-hot industry at pre-IPO prices.
Synairgen Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/27/2022||Bruce Campbell||Insider||Buy||621||GBX 189||£1,173.69|
|8/12/2021||John C Ward||Insider||Sell||269,963||GBX 140||£377,948.20|
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
The US-China "Lithium War" Is Creating Opportunity
SEC Filings (Institutional Ownership Changes) for Synairgen (LON:SNG)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Now: GBX 29.67
50 Day Range
MA: GBX 24.48
52 Week Range
Now: GBX 29.67
Who are the company insiders with the largest holdings of Synairgen?